BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 08, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 2/5 cls
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Wedbush Y. Katherine Xu Upgrade Market outperform (from neutral) 1% $2.38
Xu cited increased confidence Achillion will partner ACH-1625, a selective inhibitor of HCV NS3 protease in Phase Ib testing. She said Phase Ib data showed that ACH-1625's potency as a single agent was at the high end of competitor HCV protease inhibitors in the clinic (see BioCentury, Jan. 18, 2010).
Acorda Therapeutics Inc. (NASDAQ:ACOR) Baird Christopher Raymond Downgrade Neutral (from market outperform) 9% $30.62
Deutsche Bank Mark Schoenebaum Price target Buy
Hapoalim Raghuram Selvaraju Price target Buy
Lazard Joel Sendek Price target Buy
Raymond said Ampyra dalfampridine (formerly Fampridine-SR) is poised for a strong launch based on favorable label and pricing, but thinks this already is reflected in the shares and he sees few near-term catalysts. Last month, FDA approved the sustained-release formulation of 4-aminopyridine to improve walking ability in patients with multiple sclerosis (MS). Acorda, which has rights to...

Read the full 1275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >